Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 10/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 0.70 |
| ▸ | TP53 | P04637 | 4/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | PTGES | O14684 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17478238 | 0.89 | GPBAR1 (0.89) | GPBAR1TP53HTT | |
| SCHEMBL17478214 | 0.89 | GPBAR1 (0.80) | GPBAR1TSHRTP53PTGES | |
| SCHEMBL880245 | 0.89 | GPBAR1 (0.80) | GPBAR1TSHRTP53CYP3A4NPSR1 | |
| SCHEMBL17478025 | 0.88 | GPBAR1 (0.83) | GPBAR1TSHRTP53HTT | |
| SCHEMBL17478043 | 0.88 | GPBAR1 (1.00) | GPBAR1TSHRTP53HTT | |
| SCHEMBL17478107 | 0.86 | GPBAR1 (1.00) | GPBAR1TP53HTT | |
| SCHEMBL17478048 | 0.86 | GPBAR1 (1.00) | GPBAR1TP53 | |
| SCHEMBL17478212 | 0.85 | GPBAR1 (0.82) | GPBAR1TP53HTT | |
| SCHEMBL880189 | 0.84 | GPBAR1 (0.80) | GPBAR1TP53HTT | |
| SCHEMBL880203 | 0.83 | TP53 (0.89) | GPBAR1TSHRTP53CYP3A4NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932309-B2 | 2-oxo-3,4-dihydropyridine-5-carboxylates and their use | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2018-04-03 | — | — | US | disclosed |
| US-9932309-B2 | 2-oxo-3,4-dihydropyridine-5-carboxylates and their use | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2018-04-03 | — | — | US | disclosed |
| US-9932309-B2 | 2-oxo-3,4-dihydropyridine-5-carboxylates and their use | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2018-04-03 | — | — | US | disclosed |
| US-20170210710-A1 | 2-OXO-3,4-DIHYDROPYRIDINE-5-CARBOXYLATES AND THEIR USE | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-07-27 | — | — | US | disclosed |
| US-20170210710-A1 | 2-OXO-3,4-DIHYDROPYRIDINE-5-CARBOXYLATES AND THEIR USE | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-07-27 | — | — | US | disclosed |
| US-20170210710-A1 | 2-OXO-3,4-DIHYDROPYRIDINE-5-CARBOXYLATES AND THEIR USE | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-07-27 | — | — | US | disclosed |
| EP-3174872-A1 | 2-OXO-3,4-DIHYDROPYRIDINE-5-CARBOXYLATES AND THEIR USE | Université de Lille 2 Droit et Santé (FR) | 2017-06-07 | — | — | EP | disclosed |
| WO-2016016238-A1 | 2-OXO-3,4-DIHYDROPYRIDINE-5-CARBOXYLATES AND THEIR USE | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2016-02-04 | — | — | WO | disclosed |
| WO-2016016238-A1 | 2-OXO-3,4-DIHYDROPYRIDINE-5-CARBOXYLATES AND THEIR USE | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2016-02-04 | — | — | WO | disclosed |
| US-8440705-B2 | 2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-2-one or 2,3,4,6,7,8-hexahydro-1H-cyclopenta[g]quinolin-2-one; Alzheimer's disease | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440705-B2 | 2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-2-one or 2,3,4,6,7,8-hexahydro-1H-cyclopenta[g]quinolin-2-one; Alzheimer's disease | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2433634-A2 | Compounds, compositions and methods of inhibiting a-synuclein toxicity | The Whitehead Institute for Biomedical Research (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-1802303-B1 | COMPOUNDS, COMPOSITIONS AND METHODS OF INHIBITING A-SYNUCLEIN TOXICITY | WHITEHEAD BIOMEDICAL INST (US) | 2011-11-02 | — | — | EP | disclosed |
| US-20100004277-A1 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20100004277-A1 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20080261953-A1 | Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261953-A1 | Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2008-10-23 | — | — | US | disclosed |
| WO-2007089548-A2 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261953-A1 | Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity | SNCA, PARK7, HTT | GPBAR1 3453/4885TSHR 3894/4885TP53 1529/4885 |
| US-20170210710-A1 | 2-OXO-3,4-DIHYDROPYRIDINE-5-CARBOXYLATES AND THEIR USE | CYP3A5, CYP2D6, QDPR | GPBAR1 1068/4885TSHR 4623/4885TP53 3689/4885 |
| US-20100004277-A1 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | GOLT1B, NPC1L1, NPC1 | GPBAR1 1890/4885TSHR 4330/4885TP53 3445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.